News | June 06, 2026
Alembic Pharma receives USFDA approval for Haloperidol tablets
The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical
The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
This facility plays an important role in Granules’ global manufacturing and supply network
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
Subscribe To Our Newsletter & Stay Updated
